Clinical Data Data could move J&J’s Talvey earlier in myeloma therapy PharmaphorumJohnson Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.HematologyRead full story pharminent June 15, 2026 (Last updated: June 15, 2026) Pharmaphorum Johnson Johnson’s Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatmentNext: Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
